{"id":"W4318485463","doi":"10.1038/s41375-023-01829-9","title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Bosutinib; Discontinuation; Medicine; Tolerability; Internal medicine; Adverse effect; Imatinib; Myeloid leukemia; Clinical endpoint; Oncology; Nilotinib; Gastroenterology; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006580261,0.001246932,0.002064679,0.001008569,0.0002428534,0.00006392767,0.0005770461,0.0005714453,0.0008064163],"category_scores_gemma":[0.0002128118,0.001076608,0.0005135427,0.002804939,0.0005875226,0.0003932861,0.0004551275,0.001004218,0.0009115489],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.05638258,"about_ca_system_score_gemma":0.01025435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001859389,"about_ca_topic_score_gemma":0.0038302,"domain_scores_codex":[0.9928457,0.0002249143,0.001721988,0.001762605,0.001350855,0.00209394],"domain_scores_gemma":[0.9958442,0.0002985392,0.0007450392,0.002088875,0.0002689336,0.0007543418],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0334122,0.002312874,0.2072072,0.008282974,0.003217472,0.01990634,0.008046589,0.005854462,0.550795,0.000215197,0.04216099,0.1185888],"study_design_scores_gemma":[0.3367937,0.01935564,0.09623286,0.01293235,0.002629755,0.001752902,0.000527885,0.01564205,0.4970107,0.00003814941,0.01372144,0.003362593],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908283,0.002944916,0.00001327205,0.0002002101,0.0004011803,0.002899867,0.0001509573,0.0006697025,0.001891647],"genre_scores_gemma":[0.9832115,0.0008227549,0.0001849991,0.0001415457,0.0009314298,0.0004922504,0.001649854,0.0003306667,0.01223497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3033815,"threshold_uncertainty_score":0.9998664,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02015551723185398,"score_gpt":0.2940192947944369,"score_spread":0.2738637775625829,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}